New Study Reveals Coke, Pepsi, and Nestle as Top Plastic Polluters 
Juventus Partners with Two Circles in Bid to Globalize Brand and Enhance Partnerships 
Nestlé Crushes Two Million Perrier Drinks Due to Contamination 
DeepL Unleashes AI-Powered Tool for Business Writing 
PepsiCo Recalls Another Popular Soda Brand 
Aramco Becomes FIFA’s 6th Global Partner Joining Adidas, Coca-Cola, Qatar Airways, Hyundai, and Visa 
Domino's Launches Innovative 'You Tip, We Tip' Promotion 
Warner Bros Discovery Dives Into Data-Driven Ad Business, Debuts Data Platform 
Nestle Reports Sales Dip Amid Price Hikes 
Remy Cointreau Surprises with Lesser Decline in Sales Thanks to China Boost 
Binance Reassures Filipino Users Amid SEC App Removal Request, Urges Balanced Review by Google and Apple 
GS25 Launches Limited-Edition Makgeolli ‘Seoul Silver’ in Korea 
The Future of Gold Trading: Technological Advances and Market Predictions in the Philippines 
Inditex Re-enters Venezuelan Market with Zara Store Opening 
Tesla Cybertruck Spotted in Sydney Sparks Debate: Potential Australian Release? 
BURLINGTON, Mass., March 03, 2017 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will present at two upcoming investor conferences:
- Raymond James 38th Annual Institutional Investors Conference
Dr. Clayman will present on Tuesday, March 7, 2017 at 7:30 a.m. EST
- Cowen & Company 37th Annual Health Care Conference
Dr. Clayman will present on Wednesday, March 8, 2017 at 8:00 a.m. EST
To access the live webcast and subsequent archived recordings for the presentations, please visit the Flexion website at http://flexiontherapeutics.com/.
About Flexion Therapeutics
Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA). The company's lead product candidate, ZilrettaTM (FX006), is being investigated for its potential to provide improved analgesia for the millions of U.S. patients who receive intra-articular injections for OA related knee pain annually.
Corporate Contacts: Fred Driscoll Chief Financial Officer Flexion Therapeutics, Inc. T: 781-305-7763 [email protected] Scott Young Sr. Director, Corporate Communications & Investor Relations Flexion Therapeutics, Inc. T: 781-305-7194 [email protected]
